New polymer carrier targeting to angiogenic endothelial cells will be designed. The cationic polymer, polyethylenimine (PEI) will be conjugated with the avb31avb5 integrin binding RGD-4C peptide, ACDCRGDCFC via hydrophilic polyethylene glycol (PEG) spacer. This designed carrier will be used for the delivery of antiangiognesis plasmids. The significant over expression of alpha-v-Beta3 and alpha-v-Beta5 integrins in angiogenic endothelial cells provides specific targeting of solid tumors compared to normal tissue, PEI condenses DNA and is endosomotropic, thereby protecting and delivering antiangiogenic plasmid DNA into target cells. In addition, the PEG spacer increases the solubility of the carrier and reduces PEI toxicity. Furthermore, this polymeric carrier is nonimmunogenic and for practical purposes can be easily mass-produced. Using the PEI-PEG-RGD carrier, preliminary data shows high specificity and transfection of plasmid DNA to the target cells. Plasmid constructs will be generated containing the endogeneous angiogenic inhibitors, solublized Flt-1 and FIk-1 receptors and the newly constructed therapeutic gene, pDHFR-p53. After extensive characterization, in vitro studies, rat malignant glioma, and murine lewis lung carcinoma animal models will be used (local and systemic delivery routes) with the carrier. A number of endogenous inhibitors targeting tumor vasculature have been studied and their systemic administration in animals suppresses the growth of tumor and metastases. However, production of recombinant proteins has proven to be difficult and high doses are required for effective treatment. In addition, systemic protein therapy includes repeated injections for prolonged treatment, which is inconvenient for administration and costly. Gene therapy, utilizing these endogenous angiogenesis inhibitors, can alleviate these problems. The results will be valuable assets to provide criteria for gene delivery in the treatment of cancer using antiangiogenesis genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA107070-02
Application #
6878563
Study Section
Surgery and Bioengineering Study Section (SB)
Program Officer
Fu, Yali
Project Start
2004-04-01
Project End
2009-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
2
Fiscal Year
2005
Total Cost
$275,828
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Lee, Won Jai; Lee, Ju Hee; Ahn, Hyo Min et al. (2015) Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model. Plast Reconstr Surg 136:328e-337e
Lee, Jung-Sun; Oh, Eonju; Yoo, Ji Young et al. (2015) Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget 6:4051-65
Moon, Chang Yoon; Choi, Joung-Woo; Kasala, Dayananda et al. (2015) Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus. Biomaterials 41:53-68
Jung, Soo-Jung; Kasala, Dayananda; Choi, Joung-Woo et al. (2015) Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model. Biomacromolecules 16:87-96
Lee, Cho-Hee; Kasala, Dayananda; Na, Youjin et al. (2014) Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials 35:5505-16
Lee, Young Sook; Kim, Sung Wan (2014) Bioreducible polymers for therapeutic gene delivery. J Control Release 190:424-39
Kasala, Dayananda; Choi, Joung-Woo; Kim, Sung Wan et al. (2014) Utilizing adenovirus vectors for gene delivery in cancer. Expert Opin Drug Deliv 11:379-92
Kim, J; Nam, H Y; Choi, J W et al. (2014) Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer. Gene Ther 21:476-83
Kim, Hyun Ah; Nam, Kihoon; Kim, Sung Wan (2014) Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials 35:7543-52
Florinas, Stelios; Kim, Jaesung; Nam, Kihoon et al. (2014) Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release 183:1-8

Showing the most recent 10 out of 37 publications